Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACADNASDAQ:AKRONASDAQ:COLLNASDAQ:RNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$21.96+2.3%$16.96$13.40▼$25.23$3.68B0.471.93 million shs439,555 shsAKROAkero Therapeutics$50.91+0.4%$41.36$17.86▼$58.40$4.06B-0.12982,804 shs535,421 shsCOLLCollegium Pharmaceutical$29.29-0.1%$28.00$23.23▼$42.29$941.15M0.63420,638 shs94,329 shsRNAAvidity Biosciences$34.48+3.9%$29.03$21.51▼$56.00$4.16B11.44 million shs385,212 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals-0.60%-2.32%+44.00%+17.58%+42.19%AKROAkero Therapeutics-0.57%+9.43%+13.06%+13.92%+169.55%COLLCollegium Pharmaceutical-0.27%+1.56%+6.00%+4.53%-11.56%RNAAvidity Biosciences+7.07%+8.47%+3.01%+16.14%+23.49%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACADACADIA Pharmaceuticals3.3367 of 5 stars3.32.00.00.03.14.21.3AKROAkero Therapeutics3.9385 of 5 stars3.53.00.04.72.11.70.0COLLCollegium Pharmaceutical4.1428 of 5 stars3.40.00.03.04.20.82.5RNAAvidity Biosciences2.4918 of 5 stars4.50.00.00.04.30.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.64Moderate Buy$26.8322.19% UpsideAKROAkero Therapeutics 3.00Buy$82.5062.05% UpsideCOLLCollegium Pharmaceutical 2.80Moderate Buy$43.8049.54% UpsideRNAAvidity Biosciences 3.00Buy$66.3892.53% UpsideCurrent Analyst Ratings BreakdownLatest COLL, AKRO, RNA, and ACAD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025AKROAkero TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$63.00 ➝ $64.005/21/2025ACADACADIA PharmaceuticalsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$20.00 ➝ $35.005/20/2025ACADACADIA PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetEqual Weight ➝ Equal Weight$20.00 ➝ $24.005/19/2025ACADACADIA PharmaceuticalsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$28.00 ➝ $31.005/19/2025ACADACADIA PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$20.00 ➝ $23.005/19/2025ACADACADIA PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$26.00 ➝ $26.005/19/2025ACADACADIA PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$24.00 ➝ $28.005/19/2025ACADACADIA PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$27.00 ➝ $30.005/19/2025ACADACADIA PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$27.00 ➝ $32.005/16/2025ACADACADIA PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform5/13/2025AKROAkero TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$80.00 ➝ $78.00(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$996.28M3.69N/AN/A$2.63 per share8.35AKROAkero TherapeuticsN/AN/AN/AN/A$9.61 per shareN/ACOLLCollegium Pharmaceutical$664.28M1.42$10.61 per share2.76$5.99 per share4.89RNAAvidity Biosciences$8.93M465.50N/AN/A$6.76 per share5.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals-$61.29M$1.3728.1528.89N/A13.83%25.83%14.71%8/5/2025 (Estimated)AKROAkero Therapeutics-$151.76M-$1.95N/AN/AN/AN/A-32.46%-29.83%8/8/2025 (Estimated)COLLCollegium Pharmaceutical$48.15M$1.2212.634.87N/A14.78%104.67%18.38%8/14/2025 (Estimated)RNAAvidity Biosciences-$212.22M-$3.00N/AN/AN/A-2,772.45%-27.66%-24.56%8/8/2025 (Estimated)Latest COLL, AKRO, RNA, and ACAD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AKROAkero Therapeutics-$1.01$0.90+$1.91$0.90N/AN/A5/8/2025Q1 2025COLLCollegium Pharmaceutical$1.50$1.49-$0.01$0.07$174.96 million$177.76 million5/8/2025Q1 2025RNAAvidity Biosciences-$0.88-$0.90-$0.02-$0.90$2.63 million$1.60 million5/7/2025Q1 2025ACADACADIA Pharmaceuticals$0.10$0.11+$0.01$0.11$239.32 million$244.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/AAKROAkero TherapeuticsN/AN/AN/AN/AN/ACOLLCollegium PharmaceuticalN/AN/AN/AN/AN/ARNAAvidity BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A2.292.11AKROAkero Therapeutics0.0517.2517.25COLLCollegium Pharmaceutical3.430.970.88RNAAvidity BiosciencesN/A17.7617.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%AKROAkero TherapeuticsN/ACOLLCollegium PharmaceuticalN/ARNAAvidity BiosciencesN/AInsider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals26.50%AKROAkero Therapeutics7.94%COLLCollegium Pharmaceutical2.51%RNAAvidity Biosciences3.83%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510167.36 million119.30 millionOptionableAKROAkero Therapeutics3079.72 million64.26 millionOptionableCOLLCollegium Pharmaceutical21032.13 million30.97 millionOptionableRNAAvidity Biosciences190120.52 million114.92 millionOptionableCOLL, AKRO, RNA, and ACAD HeadlinesRecent News About These CompaniesAmeriprise Financial Inc. Has $798,000 Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)June 3 at 3:11 AM | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Makes New Investment in Avidity Biosciences, Inc. (NASDAQ:RNA)June 2 at 4:41 AM | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Lowers Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)June 1 at 4:22 AM | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Rating of "Buy" from BrokeragesJune 1 at 3:48 AM | marketbeat.comNuveen Asset Management LLC Sells 706,062 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)May 29, 2025 | marketbeat.comBank of America Corp DE Sells 1,164,431 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)May 29, 2025 | marketbeat.comVoloridge Investment Management LLC Purchases 134,489 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)May 28, 2025 | marketbeat.comWaverly Advisors LLC Takes $259,000 Position in Avidity Biosciences, Inc. (NASDAQ:RNA)May 28, 2025 | marketbeat.comSquarepoint Ops LLC Raises Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)May 27, 2025 | marketbeat.comBNP Paribas Financial Markets Takes Position in Avidity Biosciences, Inc. (NASDAQ:RNA)May 26, 2025 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Shares Purchased by Neo Ivy Capital ManagementMay 25, 2025 | marketbeat.comTwinbeech Capital LP Takes Position in Avidity Biosciences, Inc. (NASDAQ:RNA)May 25, 2025 | marketbeat.comProShare Advisors LLC Raises Position in Avidity Biosciences, Inc. (NASDAQ:RNA)May 25, 2025 | marketbeat.comCastleark Management LLC Increases Position in Avidity Biosciences, Inc. (NASDAQ:RNA)May 24, 2025 | marketbeat.comWoodline Partners LP Has $25.18 Million Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)May 23, 2025 | marketbeat.comMIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $4.21 Million Position in Avidity Biosciences, Inc. (NASDAQ:RNA)May 22, 2025 | marketbeat.comAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 21, 2025 | prnewswire.comDeutsche Bank AG Purchases 30,340 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)May 21, 2025 | marketbeat.comRafferty Asset Management LLC Sells 22,381 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)May 20, 2025 | marketbeat.comMan Group plc Sells 487,710 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)May 20, 2025 | marketbeat.comBioscience Firms in Southern California Focus on Innovation & CollaborationMay 18, 2025 | latimes.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueBigBear.ai: Risky AI Stock or Defense Tech Opportunity?By Jeffrey Neal Johnson | May 28, 2025View BigBear.ai: Risky AI Stock or Defense Tech Opportunity?These ETFs Provide Easy Exposure to Growing International MarketsBy Nathan Reiff | May 24, 2025View These ETFs Provide Easy Exposure to Growing International MarketsNike’s Amazon Expansion Could Signal a Turnaround in 2025By Gabriel Osorio-Mazilli | May 30, 2025View Nike’s Amazon Expansion Could Signal a Turnaround in 2025COLL, AKRO, RNA, and ACAD Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$21.96 +0.49 (+2.28%) As of 12:40 PM EasternACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Akero Therapeutics NASDAQ:AKRO$50.91 +0.18 (+0.35%) As of 12:38 PM EasternAkero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Collegium Pharmaceutical NASDAQ:COLL$29.29 -0.02 (-0.07%) As of 12:31 PM EasternCollegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Avidity Biosciences NASDAQ:RNA$34.48 +1.31 (+3.95%) As of 12:39 PM EasternAvidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Steel Dynamics Shares Climb After Tariff Announcement Why Super Micro Computer's Upside Could Trigger a Short Squeeze Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Ulta’s Beautiful Q1 Earnings Report Points to More Gains Ahead Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Chewy Stock Gets a New $7.1 Billion Investor and Analyst Upgrade Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
